Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
Zachary KlaassenLauren E HowardChristopher J D WallisJessica L JanesAmanda M De HoedtWilliam J AronsonThomas J PolascikChristopher J AmlingChristopher J KaneMatthew R CooperbergMartha K TerrisYuan WuStephen J FreedlandPublished in: Prostate cancer and prostatic diseases (2022)
Given the high correlation between CRPC-FS and MFS, after validation, CRPC-FS may serve as a potential intermediate endpoint in trials for men with BCR initiating ADT following local therapy.